Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 11/20 | 0.61 |
| ▸ | MME | P08473 | 8/20 | 0.61 |
| ▸ | ACE | P12821 | 4/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865941 | 1.00 | MMEL1 (0.61) | MMEL1MMEACETAAR1FFAR1 | |
| Hydrochloric Acid SCHEMBL1912620 | 0.99 | MMEL1 (0.60) | MMEL1MMEACETAAR1FFAR1 | |
| Hydrochloric Acid SCHEMBL1912565 | 0.99 | MMEL1 (0.60) | MMEL1MMEACETAAR1FFAR1 | |
| SCHEMBL10197790 | 0.88 | TAAR1 (0.53) | MMEL1MMEACETAAR1FFAR1 | |
| SCHEMBL2032416 | 0.85 | FFAR1 (0.55) | MMEL1FFAR1 | |
| SCHEMBL29556848 | 0.85 | FFAR1 (0.55) | MMEL1FFAR1 | |
| SCHEMBL11827456 | 0.84 | MMEL1 (0.62) | MMEL1MMEACETAAR1FFAR1 | |
| SCHEMBL1256346 | 0.84 | PNMT (0.57) | TAAR1FFAR1 | |
| SCHEMBL29478402 | 0.84 | PNMT (0.57) | TAAR1FFAR1 | |
| SCHEMBL29478393 | 0.84 | PNMT (0.57) | TAAR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594556-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2594557-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2640375-B1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2016-05-18 | — | — | EP | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2435409-B1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2640375-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| EP-2594557-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594556-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8394853-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2435409-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010136493-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | MMEL1 299/4885MME 1/4885ACE 4/4885 |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | MMEL1 299/4885MME 1/4885ACE 4/4885 |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MMEL1 118/4885MME 3/4885ACE 92/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MMEL1 118/4885MME 3/4885ACE 92/4885 |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | MMEL1 299/4885MME 1/4885ACE 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.